Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli

Kimberly A. Kline  
Washington University School of Medicine in St. Louis

Drew J. Schwartz  
Washington University School of Medicine in St. Louis

Nicole M. Gilbert  
Washington University School of Medicine in St. Louis

Scott J. Hultgren  
Washington University School of Medicine in St. Louis

Amanda L. Lewis  
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/2562

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Infection and Immunity

Immune Modulation by Group B Streptococcus Influences Host Susceptibility to Urinary Tract Infection by Uropathogenic Escherichia coli

Kimberly A. Kline, Drew J. Schwartz, Nicole M. Gilbert, Scott J. Hultgren and Amanda L. Lewis

Updated information and services can be found at:
http://iai.asm.org/content/80/12/4186

These include:

REFERENCES
This article cites 69 articles, 43 of which can be accessed free at:
http://iai.asm.org/content/80/12/4186#ref-list-1

CONTENT ALERTS
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Immune Modulation by Group B Streptococcus Influences Host Susceptibility to Urinary Tract Infection by Uropathogenic Escherichia coli

Kimberly A. Kline,* Drew J. Schwartz, Nicole M. Gilbert, Scott J. Hultgren, and Amanda L. Lewis

Department of Molecular Microbiology, Center for Women’s Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri, USA

Urinary tract infection (UTI) is most often caused by uropathogenic Escherichia coli (UPEC). UPEC inoculation into the female urinary tract (UT) can occur through physical activities that expose the UT to an inherently polymicrobial periurethral, vaginal, or gastrointestinal flora. We report that a common urogenital inhabitant and opportunistic pathogen, group B Streptococcus (GBS), when present at the time of UPEC exposure, undergoes rapid UPEC-dependent exclusion from the murine urinary tract, yet it influences acute UPEC-host interactions and alters host susceptibility to persistent outcomes of bladder and kidney infection. GBS presence results in increased UPEC titers in the bladder lumen during acute infection and reduced inflammatory responses of murine macrophages to live UPEC or purified lipopolysaccharide (LPS), phenotypes that require GBS mimicry of host sialic acid residues. Taken together, these studies suggest that despite low titers, the presence of GBS at the time of polymicrobial UT exposure may be an overlooked risk factor for chronic pyelonephritis and recurrent UTI in susceptible groups, even if it is outcompeted and thus absent by the time of diagnosis.

Received 6 July 2012  Returned for modification 1 September 2012
Accepted 7 September 2012
Published ahead of print 17 September 2012
Editor: S. R. Blanke
Address correspondence to Amanda L. Lewis, allewis@wustl.edu, or Scott J. Hultgren, hultgren@borcim.wustl.edu.
* Present address: Kimberly A. Kline, Singapore Centre on Environmental Life Sciences Engineering, School of Biological Sciences, Nanyang Technological University, Singapore.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.00684-12

4186 iai.asm.org  Infection and Immunity  p. 4186–4194 December 2012 Volume 80 Number 12
chronic cystitis characterized by persistent, high-titer bacteriuria (>10⁴ CFU/ml), as well as high-titer bacterial bladder burdens at sacrifice >4 weeks postinfection (wpi), chronic inflammation, and urothelial necrosis. Severe pyuria and elevated levels of interleukin 6 (IL-6), granulocyte colony-stimulating factor (G-CSF), keratinocyte-derived chemokine (KC), and IL-5 in serum within the first 24 hpi precede chronic infection in C3H/HeN mice and are greater than 95% predictive of future development of chronic UTI (17).

Despite a strong acute inflammatory response directed toward UPEC, C3H/HeN mice not only are susceptible to acute cystitis but also often develop high-titer chronic cystitis and chronic ascending pyelonephritis (17, 23). Recent studies show that elevated systemic inflammatory cytokine responses are prognostic indicators of chronic cystitis development by UPEC (17). In contrast, the related C3H/HeJ mouse strain, which lacks functional TLR4 responses to Gram-negative lipopolysaccharide (LPS) (24, 47), exhibits higher-titer cystitis and pyelonephritis than C3H/HeN mice, without evidence of significant histological inflammation (16, 19, 23, 54, 56). Taken together, these data provide a detailed understanding of monomicrobial UPEC infection, particularly in the C3H/HeN and C3H/HeJ mouse backgrounds, although UPEC pathogenesis and IBC formation have also been studied in C57BL/6J, CBA/J, and FVB/NJ mice (13). We employed the C3H/HeN and C3H/HeJ models to investigate whether the presence of a common urogenital inhabitant and potential pathogen, group B streptococcus (GBS), at the time of UPEC exposure can fundamentally alter the cellular or molecular dynamics of UPEC-host interactions.

GBS is a Gram-positive bacterium that asymptptomatically colonizes the lower gastrointestinal, vaginal, and/or urinary tract in up to 65% of healthy women (38). While the bacterium has evolved to coexist peacefully in most immunocompetent adults, certain susceptible individuals, such as newborns, pregnant women, and the elderly, are at higher risks of developing invasive GBS infections (59, 70). GBS is best known as a leading cause of pneumonia, bacteremia, sepsis, and meningitis in newborns (5, 70). A less recognized focus of infection for GBS is the UT. GBS causes about 1% of all monomicrobial UTIs (approximately 80,000 annually), which occur largely in immunocompromised, diabetic, elderly, and pregnant populations (11, 65). We recently demonstrated that GBS mediates both immune suppression and activation in a murine model of UTI (32). GBS uses sialic acid residues of its capsular polysaccharide to suppress oxidative burst, responses of murine polymorphonuclear cells (PMNs), and naturally high levels of sialic acid O-acetylation (OAc⁶⁺ strain) block the ability of GBS to suppress PMNs compared to an isogenic OAc⁶⁻ strain (32, 68). We further showed that GBS OAc⁶⁺ organisms, which were capable of suppressing PMN oxidative burst, survived better in the urinary tract of C3H/HeN mice than the isogenic OAC⁶⁻ strain (32, 68). In this study, we investigated the hypothesis that GBS presence within a polymicrobial UT exposure may shape inflammatory processes that influence host-UPEC interactions. We show that GBS can influence long-term outcomes of UPEC UTI despite its own rapid elimination in the presence of UPEC. Further, we present evidence that prior to its demise, GBS employs sialic acid residues of its capsular polysaccharide to fundamentally alter the cellular dynamics of early UPEC-host interactions.

MATERIALS AND METHODS

Bacterial strains and growth conditions. Wild-type (WT) uropathogenic E. coli strain UTI89 (39), UTI89 attB307::COM-GFP (kanamycin resistant [Kan⁺]) (69), UTI89 FimH Q133K (SLC2-35-1) (6), and UTI89 FimH wild-type control strain (SLC2-33-1) (6) were inoculated from single colonies grown on LB agar into LB broth, containing kanamycin at 25 μg/ml where appropriate, and grown statically overnight (18 to 24 h) at 37°C. In the wild-type UPEC strains under investigation, these standardly used growth conditions result in optimal expression of type 1 pili (6, 28), necessary for establishing a urinary tract infection. Streptococcus agalactiae (also called group B streptococcus [GBS]) wild-type strain COH1, a well-characterized strain that expresses low levels of the β-hemolysin and high levels of the capsular polysaccharide, or isogenic mutants of GBS COH1 expressing sialic acids with minimal O-acetylation (OAc⁶⁻) or hyper-O-acetylation of sialic acids (OAc⁶⁺) (34, 35, 67, 68) were used in these studies. As previously described, the WT COH1 strain has an intermediate level of O-acetylation (67). For all experiments, GBS was inoculated from single colonies grown on Todd-Hewitt (TH) agar into TH broth with antibiotics where appropriate, grown statically overnight, and then diluted 1:10 in fresh TH broth for an additional 1 to 2 h at 37°C to an optical density at 600 nm (OD₆₀₀) of approximately 0.4 (logarithmic phase) as previously described for GBS UTI and other in vivo virulence studies (9, 32, 68).

Murine infections. Bacterial cultures, grown as described above, were collected by centrifugation and resuspended in phosphate-buffered saline (PBS). Female wild-type mice, 7 to 10 weeks of age, were obtained from Harlan (C3H/HeN) or the Jackson Laboratories (C3H/HeJ). Mice were anesthetized by inhalation of 3% isoflurane. Mice were then voided prior to transurethral bacterial inoculation with 1 x 10⁷ CFU of each organism. Mice were then voided prior to transurethral bacterial inoculation with 1 x 10⁷ to 2 x 10⁷ CFU per organ. At various time points, mice were euthanized and bladders and kidneys were aseptically removed. The number of bacteria present in the tissues was determined by homogenization of bladders or kidney pairs in PBS and plating of serial dilutions on LB or TH agar. For coinfection studies, samples were plated on MacConkey agar and Columbia CNA agar plus 5% sheep blood, supplemented with antibiotics when appropriate, to differentiate between Gram-negative and Gram-positive bacteria, respectively. Alternately, ex vivo gentamicin protection assays were performed on excised bladders to assess the extracellular and intracellular populations in the bladder (29). Briefly, bladders were removed at 3 hpi, quadrisection to assist in thorough washing of the tissue, and washed 3 times in 500 μl fresh PBS with gentle mixing. Enumeration of total CFU from the 3 pooled washes indicates luminal or loosely attached extracellular bacteria. Gentamicin treatment (100 μg/ml) proceeded at 37°C for 90 min, followed by thorough washing, homogenization, and enumeration of gentamicin-protected bacteria. The supernatant from the gentamicin treatment was plated separately on nonselective media to ensure that all extracellular UPEC and/or GBS organisms were killed by the gentamicin during the incubation. Statistical analyses were performed using the Mann-Whitney test with GraphPad Prism software (version 5.00 for Windows; GraphPad Software). Recovered titers of 0 are graphed at the limit of detection of the assay, and median titers are indicated in all figures. All animal studies were performed in accordance with the Committee for Animal Studies at Washington University School of Medicine.

Cytokine measurement. UPEC, GBS, and UPEC plus GBS were inoculated into mouse bladders as described above, and venous blood was collected at 24 hpi by submandibular puncture into 400-μl Microtainer serum separation tubes (BD). After coagulation, Microtainer tubes were subjected to centrifugation at 15,000 x g for 5 min at 4°C and stored at −20°C. Cytokine expression was measured using the Bio-Plex multiplex cytokine bead kit (Bio-Rad), which measures 23 different proinflammatory cytokines. Statistical analyses were performed in GraphPad Prism using the Mann-Whitney U test.
NF-κB assays. RAW-Blue cells (murine RAW 264.7 macrophages with chromosomal integration of a secreted embryonic alkaline phosphatase [SEAP] reporter construct inducible by NF-κB; Invivogen) were maintained in Dulbecco modified Eagle medium (DMEM), 4.5 g/liter glucose, 2 to 4 mM L-glutamine, 10% (vol/vol) fetal bovine serum, 50 U/ml penicillin, 50 µg/ml streptomycin, 100 µg/ml Normocin, and 200 mg/ml Zeocin at 37°C in 5% CO₂. For infection experiments, cells were seeded into a 96-well plate (Falcon Microtest tissue culture plate, flat bottom, low evaporation lid, catalog no. 35307; BD) at ~100,000 cells/well in 200 µl antibiotic-free medium, according to the supplier’s instructions. After overnight incubation, cells were washed with PBS, and 180 µl fresh medium was added. Wells (triplicate for each condition) were treated with 20 µl LPS from E. coli O26:B6 at 10 µg/ml (catalog no. L2654; Sigma) empirically determined for optimal SEAP activity in LPS dilution series experiments. Cells were also infected with GBS, UPEC, or GBS plus UPEC (at a 20:1, 10:1, or 1:1 ratio of bacteria to macrophage) in PBS or PBS only as a mock-infected control and incubated at 37°C in 5% CO₂. At 6 hpi, 20 µl supernatant was removed and added to 180 µl QUANTI-Blue (Invivogen), the mixture was incubated at 37°C overnight, and SEAP levels were determined at 640 nm. Results shown depict one representative experiment of at least three biologically independent experiments performed. Lactate dehydrogenase assays (Clontech) were performed according to the manufacturer’s instructions on macrophage supernatants after exposure to WT GBS for 6 h.

RESULTS

Bladder coexposure to GBS and UPEC alters host interactions with both organisms. To investigate the impact of bacterial co-occurrence on the early cellular dynamics of host-microbe interactions in the bladder, we measured luminal- and tissue-associated titers of GBS and UPEC following mono- and coinfections. In order to evaluate the number of bacteria that had invaded the bladder tissue 3 h after transurethral exposure to bacteria (GBS, UPEC, or coinfected GBS and UPEC), an ex vivo gentamicin protection assay was performed on each murine bladder (39). Extracellular bacteria surviving in the bladder lumen were measured from tissue washes prior to gentamicin treatment, followed by recovery and enumeration of gentamicin-protected, tissue-associated bacteria. In these experiments, extracellular UPEC CFU were significantly elevated in the lumen at 3 hpi in the presence of GBS compared to UPEC alone (Fig. 1A). The ability of UPEC to invade the urothelium and enter gentamicin-protected intracellular compartments was not altered by the presence of GBS (Fig. 1B). While UPEC presence led to an apparent reduction of GBS fitness in the acutely coinfected bladder lumen, UPEC did not affect the ability of GBS to occupy a gentamicin-protected niche (Fig. 1B). This is, to our knowledge, the first report that GBS, like UPEC, can inhabit gentamicin-protected bladder tissue compartments in vivo. We obtained identical growth curves for GBS and UPEC during mono- and coculture of the organisms in vitro, strongly suggesting that host factors contribute to the observed population dynamics in the bladder (Fig. 1C). These data show that GBS accesses multiple bladder niche environments within the first few hours of coinfection and leads to increased fitness of UPEC in the bladder lumen during acute infection.

GBS capsule sialic acids promote UPEC survival in the bladder lumen. Previous studies have shown that bladder epithelial cells are capable of expelling invaded UPEC (60). Thus, increased luminal titers of UPEC in the presence of GBS may involve intracellular transit of UPEC followed by their expulsion into the lumen. The FimH::Q133K mutation, which abolishes the primary mannose-dependent adhesive interaction of UPEC with bladder epithelial cells (25), was used to investigate whether FimH-mediated binding and invasion of the bladder tissue were required for the enhanced early survival of UPEC in the presence of GBS. Mice were mono- or coinfected with GBS and the FimH::Q133K mutant of UPEC strain UTI89 (6). In monoinfected mice, UPEC bearing the Q133K FimH mutation was unable to bind or invade the bladder epithelium and was cleared from the bladders of most animals by 3 hpi (Fig. 2A) (6). However, we discovered that in the presence of GBS, UPEC bearing the Q133K FimH mutation survived significantly better in the acutely infected bladder lumen (Fig. 2A). In contrast, the invasion of Q133K UPEC remained defective even in the presence of GBS, as determined by gentamicin protection (Fig. 2A). GBS-mediated enhancement of UPEC bearing FimH::Q133K was limited to acute infection and was not observed at 24 hpi (data not shown). These results demonstrate that FimH-mediated attachment and invasion by UPEC are not required for GBS augmentation of UPEC survival in the bladder lumen.

We recently showed that GBS capsular sialic acid residues sup-
pressed PMN oxidative burst responses and enhance GBS survival in the urinary tract of C3H/HeN mice (32, 68). To determine whether GBS capsular sialic acids also play a role in the observed GBS augmentation of UPEC survival, we analyzed intracellular and extracellular UPEC survival in the presence of isogenic GBS strains bearing high or low levels of sialic acid O-acetylation. Bladders were removed 3 h after transurethral coinoculation, followed by enumeration of luminal and intracellular GBS and UPEC organisms. While the luminal titers of GBS OAcall and OAchr strains did not differ significantly at this early time point, wild-type luminal UPEC CFU were elevated in the presence of GBS OAchr compared to GBS OAcall (Fig. 2B). There were no differences observed in the intracellular UPEC or GBS populations under any of these conditions. These results establish that GBS acts through a sialic acid-mediated mechanism to enhance UPEC titers in the bladder lumen.

GBS augmentation of UPEC in the bladder lumen occurs in C3H/HeN but not C3H/HeJ mice. To further investigate the hypothesis that GBS may suppress immune responses during acute infection, we examined the fate of UPEC in mono- or coinfected C3H/HeJ mice, which lack a functional TLR4 receptor and thus are unable to mount a robust inflammatory response to UPEC (16, 22, 53, 54). We reasoned that if GBS suppresses TLR4-mediated inflammatory responses, UPEC should derive no significant benefit from GBS in the bladder of C3H/HeJ coinfected mice, since immune responses to UPEC in this host background are already blunted. UPEC CFU in the bladder lumens of C3H/HeJ and C3H/HeN mice were compared after coinfection with GBS. Consistent with our hypothesis, C3H/HeJ mice (in contrast to their C3H/HeN counterparts) did not exhibit a GBS-dependent augmentation of UPEC titers in the bladder (Fig. 3A). Enumeration of bacterial titers in the kidneys revealed a significant GBS-dependent reduction of UPEC titers in C3H/HeJ mice compared to C3H/HeN mice (Fig. 3B). These data further support the hypothesis that GBS modulation of TLR4-dependent innate processes is likely responsible for the observed augmentation of UPEC in the acute bladder. Moreover, the data suggest that GBS may have distinct effects on UPEC-host interactions in the bladder and kidneys for reasons that are currently unknown. However, recent studies have shown that there is at least one additional

FIG 2 GBS capsule sialic acids enhance UPEC survival in the bladder lumen during acute infection. Gentamicin protection assays were performed on excised bladders (3 hpi) of mono- or coinoculated animals. (A) Lumen bladder survival assays using the bladder binding-defective UPEC FimH::Q133K mutant in the presence or absence of WT GBS. (B) Lumen bladder survival assays after coinoculation of WT UPEC and GBS capsule mutants. n = 2, at least 5 mice per experiment. The horizontal bar represents the median value for each group of mice. Statistical significance was determined by the two-tailed Mann-Whitney test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. The dashed horizontal line indicates the limit of detection of the assay. Titers below the limit of detection were assigned a value of 1 for visualization on the log scale and 0 for statistical analyses.

FIG 3 UPEC augmentation by GBS in the bladder lumen does not occur in C3H/HeJ mice. Gentamicin protection assays were performed on excised bladders (A) and kidney CFU were determined (B) in mono- or coinoculated C3H/HeN and C3H/HeJ mice at 3 hpi. UPEC bladder CFU from C3H/HeN mouse data shown here are replotted from Fig. 1A for ease of comparison with data obtained from C3H/HeJ mice. Metadata from 6 experiments are shown for C3H/HeN mice; n = 2 for C3H/HeJ mice, with at least 5 mice per experiment. The horizontal bar represents the median value for each group of mice. Statistical significance was determined by the two-tailed Mann-Whitney test. *, P < 0.05. The dashed horizontal line indicates the limit of detection of the assay. Titers below the limit of detection were assigned a value of 1 for visualization on the log scale and 0 for statistical analyses.
macrophage activation with OAchi and OAclo strains of GBS in the contribution to suppression of PMN activity (32), we investigated B-driven responses, similar to their population of macrophage NF-κB/H9260.

Gram-negative LPS. B-driven macrophage responses to NF-κB/H9260 engages in suppression of NF-κB not shown). These data demonstrate that the Gram-positive GBS (27) in supernatants of macrophages exposed to WT GBS (data phage death, as evidenced by the absence of lactate dehydrogenase apoptosis at a relatively high multiplicity of infection (MOI) though GBS has previously been shown to induce macrophage B-dependent transcription. Al-responded by upregulating NF-κB/H9260.

The hypothesis that GBS may suppress immune responses specifically resulting from LPS-TLR4 interactions was investigated by measuring the ability of GBS to affect LPS- or UPEC-driven activation of the transcription factor NF-κB in murine macrophages. Macrophages encoding a stable secreted alkaline phosphatase reporter downstream of NF-κB-responsive promoter sequences were exposed to different combinations and doses of UPEC, LPS, and/or GBS. As expected, strong induction of NF-κB-dependent transcription was observed in response to LPS alone or UPEC alone at 6 hpi in control experiments (Fig. 4A and B). In contrast, when GBS was added to macrophages together with UPEC (Fig. 4A) or LPS (Fig. 4B), macrophages no longer responded by upregulating NF-κB-dependent transcription. Although GBS has previously been shown to induce macrophage apoptosis at a relatively high multiplicity of infection (MOI) (100:1 ratio of bacteria to macrophage) following 24 h of exposure (12, 64), the lower MOI (1:1, 1:10, or 1:20) and shorter duration (6 h) of these experiments with WT GBS did not result in macrophage death, as evidenced by the absence of lactate dehydrogenase (27) in supernatants of macrophages exposed to WT GBS (data not shown). These data demonstrate that the Gram-positive GBS engages in suppression of NF-κB-driven macrophage responses to Gram-negative LPS.

To determine if GBS capsule sialic acids participate in the modulation of macrophage NF-κB-driven responses, similar to their contribution to suppression of PMN activity (32), we investigated macrophage activation with OAcβ and OAcα strains of GBS in the presence or absence of simultaneous LPS stimulation. In the absence of LPS stimulation, OAcβ GBS suppressed NF-κB-driven proinflammatory responses in murine macrophages, while high levels of sialic acid O-acetylation on the isogenic OAcα strain blocked the ability of GBS to suppress macrophage activation (Fig. 4C). A similar phenotype was observed in the presence of LPS, where OAcβ GBS suppressed LPS-induced NF-κB-driven inflammation, while OAcα GBS was unable to limit NF-κB-driven macrophage responses in the presence of LPS. This discovery adds GBS to a growing number of pathogens that can inhibit NF-κB signaling as a pathogenic strategy (33, 42). Taken together with evidence that capsule sialic acids also contribute to UPEC survival in the bladder lumen (Fig. 2A), these data strongly implicate direct immune modulation of TLR4-dependent processes by the GBS capsule in alteration of UPEC-host interactions following polymicrobial UT exposure.

GBS presence during acute UTI reduces the risk of chronic high-titer UPEC cystitis but increases the risk of latent bacterial reservoirs and the severity of ascending kidney infection. The ramifications of GBS exposure on long-term UTI outcomes were also investigated. Analysis of serum cytokines at 24 hpi was performed to examine the possibility that GBS may shift the previously described checkpoint of host acute inflammatory responses linked with the development of chronic cystitis (17). Mice were inoculated with UPEC alone or coincubated with GBS, followed by analysis of serum cytokines at 24 hpi, urine CFU over the course of infection, and bladder and kidney titers at 4 wpi. We found that the inflammatory cytokine signature previously shown to predict the development of chronic UPEC cystitis in monoinfected mice (IL-6, KC, and G-CSF) (17) also correlated with the development of chronic infection following mixed inoculation regardless of GBS dose (Fig. 5A to C); however, the proportion of mice succumbing to chronic high-titer cystitis was affected (see below). UPEC CFU in the bladder at 24 hpi, the time point at which cytokines were analyzed, did not differ between mono- and coinfected animals. In contrast, GBS had been preferentially eliminated in the presence of UPEC from most animals by 24 hpi (Fig. 5D).

Examining the consequence of coinoculation on long-term infections, we observed a unique dose-dependent effect of GBS on the development of UPEC chronic high-titer cystitis (>10⁴ CFU/ml with bacteriuria), the presence of latent UPEC reservoirs (<10⁴ CFU/ml without bacteriuria), and the ability of UPEC to cause high-titer infections of the kidney. When high-dose GBS and UPEC (~10⁷ each) were coincubated, significantly fewer
mice developed persistent bacteriuria (data not shown) and chronic cystitis (>10^4 CFU/ml) at 4 wpi compared to animals that received monomicrobial inoculation of UPEC (Fig. 6A). Instead, high-dose GBS shifted UPEC outcomes toward a lower-titer (<10^4 CFU/ml) latent reservoir as previously described (22–24). Coinfection with a slightly lower dose of GBS (approximately 2:1 ratio of UPEC to GBS) eliminated the GBS-dependent shift in UPEC outcomes toward latent reservoirs, instead rendering the animals more susceptible to high-titer chronic cystitis than with high-dose GBS (Fig. 6A). Consistent with this finding, mice coinfect with the lower dose of GBS had significantly higher UPEC titers in the bladder and kidneys at 4 wpi than with UPEC alone or high-dose GBS (Fig. 6B and C). Together, these data demonstrate that GBS presence within the first 24 h after mixed microbial ex-

FIG 5 GBS coinoculation induces cytokines associated with UPEC chronic cystitis in C3H/HeN mice. (A to C) Serum cytokine analysis at 24 hpi of C3H/HeN mice mono- and coinoculated with 10^7 UPEC UTI89 alone or coinoculated with 1 x 10^7 to 2 x 10^7 GBS COH1 CFU (high dose) or 2 x 10^6 to 9 x 10^6 GBS COH1 CFU (low dose), stratified by animals that went on to develop chronic cystitis or that resolved infection (see Fig. 6). n = 3, at least 5 mice per experiment. (D) UPEC and GBS CFU in the bladder at 24 h after transurethral inoculation with 10^7 GBS COH1 organisms alone or coinoculated with 10^7 UPEC UTI89 organisms. n = 4 experiments, with at least 5 mice per experiment. The horizontal bar represents the median value for each group of mice. The dashed horizontal line indicates the limit of detection of the assay. Titers below the limit of detection were assigned a value of 1 for visualization on the log scale and 0 for statistical analyses. For both serum cytokine levels and CFU, statistical significance was determined by the two-tailed Mann-Whitney test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

FIG 6 GBS coinoculation has dose-dependent effects on the development of chronic UPEC cystitis and pyelonephritis C3H/HeN mice. (A) The percentage of mice displaying >10^6 CFU/bladder at 4 wpi, indicative of chronic cystitis following infection of C3H/HeN mice with 10^7 GBS UTI89 organisms alone, or coinoculated with high-dose GBS (1 x 10^7 to 2 x 10^7 GBS COH1 CFU, 1:1 ratio of UPEC to GBS) or low-dose GBS (2 x 10^6 to 9 x 10^6 GBS COH1 CFU, 2:1 ratio of UPEC to GBS). Fisher's exact test was used for statistical analysis. According to previous work, animals with persistent infection with >10^4 CFU/bladder are characterized by the presence of latent quiescent reservoirs. (B) UPEC CFU in the bladder at 4 wpi. (C) UPEC CFU in the kidneys at 4 weeks following monoinoculation with UPEC or coinoculation. For CFU analysis, n = 3 to 8, at least 5 mice per experiment. The horizontal bar represents the median value for each group of mice. Statistical significance was determined by the two-tailed Mann-Whitney test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. The dashed horizontal line indicates the limit of detection of the assay. Titers below the limit of detection were assigned a value of 1 for visualization on the log scale and 0 for statistical analyses.
posure of the urinary tract strongly influences the outcome of persistent UPEC UTI.

DISCUSSION
Urinary tract infections are highly prevalent and afflict otherwise healthy individuals across their life span, from infancy to old age. Significant efforts have been made to understand the molecular mechanisms underlying UTI, focusing largely on UPEC since it is the uropathogen most frequently isolated from infected individuals. The “gold standard” laboratory model in the field takes advantage of 7- to 8-week-old female mice transurethrally infected with a single uropathogen. Studies using this model have revealed novel aspects and mechanisms for UTI pathogenesis. However, our understanding of the complexities associated with UTI susceptibility in at-risk groups and under more realistic infection conditions is limited. The results presented here demonstrate that GBS may be an underappreciated uropathogen, as it can shift complex immunological responses in the urinary tract during acute infection, altering UPEC-host interactions in ways that change the long-term consequences of infection. These findings call for further experimental and clinical studies to examine GBS, as well as other common vaginal and gut bacteria, as potential risk factors for UTI in susceptible groups, including pregnant, elderly, and immunocompromised populations.

Our findings are consistent with coinfection studies at other mucosal sites, bolstering the concept that bacterial community members within the same niche are not blind to one another but can interact in mutualistic and/or antagonistic ways (4, 45, 50). In humans, clinical UTI is associated with increased sexual intercourse frequency in the 14 days prior to diagnosis (8). It is likely that polymicrobial UT exposure occurs prior to, or as a result of, these events. When polymicrobial urine cultures are found in clinically diagnosed UTI, the general clinical paradigm in healthy, nonpregnant adults is that titers of Gram-positive bacteria of <10^5 CFU/ml of urine are etiologically and clinically insignificant. In contrast, polymicrobial UT exposure occurs prior to, or as a result of, these events. When polymicrobial urine cultures are found in clinically diagnosed UTI, the general clinical paradigm in healthy, nonpregnant adults is that titers of Gram-positive bacteria of <10^5 CFU/ml of urine are etiologically and clinically insignificant. In contrast, polymicrobial UT exposure occurs prior to, or as a result of, these events. GBS suppression of innate immune responses during acute UTI may, at optimal doses, create a more hospitable environment for UPEC, leading to the transcendence of early infection bottlenecks and alteration of long-term infection (55).

Few bacterial species exist as monocultures in their native environments, and yet, the vast majority of microbiological studies to date have been monomicrobial in nature. Recently, there has been a growing appreciation for the significance of polymicrobial infections as well as the importance of a healthy flora for resistance to infection. Synergistic polymicrobial behavior has been implicated in a variety of disease states, including sepsis (46), cystic fibrosis lung infection (20, 51, 57, 58), community-acquired respiratory infections (36, 37, 41), periodontal disease and other oral pathogen infection models (44, 48), and UTI (7, 63). Our increasing understanding of the complexity of infectious disease states and the contribution of multiple etiologic agents underscores the need for modern genetic and molecular diagnostics along with treatment tailored accordingly, a need especially important for chronic and recurrent diseases, such as UTI, that are increasingly recalcitrant to treatment.

ACKNOWLEDGMENTS
We thank Corinne Cusumano, Tom Hannan, and Patrick Olson for technical expertise; Molly Ingersoll (Mount Sinai School of Medicine) for insightful discussion; and Karen Dodson and Tom Hannan for critical reading of the manuscript.

This work was supported by NIH grants R01DK51406 to S.J.H. and R21DK092586 to A.L.L.

REFERENCES